Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening

Heart Failure Reviews

Volumn 19, Issue 6, 2014, Pages 743-758

  Holzhauser, Luise ^a   Zolty, Ronald ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Dilated cardiomyopathy; Endothelin receptor polymorphisms; Endothelin 1; Hypertension; Pulmonary hypertension; Transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; AMBRISENTAN; ANGIOTENSIN II; ASPARAGINE; ASPARTATE AMINOTRANSFERASE; BOSENTAN; CARDIOTROPHIN 1; CATECHOLAMINE; CYTOKINE; CYTOSINE; DARUSENTAN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FREE RADICAL; GROWTH FACTOR; HISTIDINE; INSULIN; LYSINE; PLACEBO; TEZOSENTAN; THROMBIN; THYMINE;

ACUTE HEART FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CELL TYPE; CLINICAL TRIAL (TOPIC); CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEADACHE; HEART MUSCLE CONTRACTILITY; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; INFLAMMATION; INOTROPISM; LEFT VENTRICULAR ASSIST DEVICE; LEG EDEMA; MEDICAL DECISION MAKING; MITOGENESIS; NONHUMAN; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHEAR STRESS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; SYSTOLIC HEART FAILURE; TREATMENT RESPONSE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; GENETICS; MASS SCREENING; METABOLISM; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIN-1; HUMANS; MASS SCREENING; POLYMORPHISM, GENETIC; RECEPTOR, ENDOTHELIN A;

EID: 84910121559     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-014-9426-y     Document Type: Article

References (156)

1. Mullol J et al (1996) Endothelin-1 induces GM-CSF, IL-6 and IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B). Neuropeptides 30(6):551–556
2. Yanagisawa M et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411–415
3. Janakidevi K et al (1992) Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 263(6 Pt 1):C1295–C1301
4. Guarda E et al (1993) Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27(12):2130–2134
5. Sakai S et al (1996) Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93(6):1214–1222
6. Pacher R et al (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27(3):633–641
7. Giaid A et al (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328(24):1732–1739
8. Stelzner TJ et al (1992) Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 262(5 Pt 1):L614–L620
9. Herrmann S et al (2001) A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 22(20):1948–1953
10. Popowski K et al (2003) Functional significance of a hereditary adenine insertion variant in the 5′-UTR of the endothelin-1 gene. Pharmacogenetics 13(8):445–451
11. Rahman T et al (2008) Common genetic variation in the type A endothelin-1 receptor is associated with ambulatory blood pressure: a family study. J Hum Hypertens 22(4):282–288
12. Mylona P, Cleland JG (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1(2):197–200
13. Kalra PR, Moon JC, Coats AJ (2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85(2–3):195–197
14. Handoko ML, de Man FS, Vonk-Noordegraaf A (2011) The rise and fall of endothelin receptor antagonists in congestive heart failure. Eur Respir J 37(3):484–485
15. McLaughlin VV et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53(17):1573–1619
16. Michael JR, Markewitz BA (1996) Endothelins and the lung. Am J Respir Crit Care Med 154(3 Pt 1):555–581
17. Inoue A et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86(8):2863–2867
18. Masaki T (1998) The discovery of endothelins. Cardiovasc Res 39(3):530–533
19. Levin ER (1995) Endothelins. N Engl J Med 333(6):356–363
20. Shinmi O et al (1989) Endothelin-3 is a novel neuropeptide: isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brain. Biochem Biophys Res Commun 164(1):587–593
21. Inoue A et al (1989) The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 264(25):14954–14959
22. Laporte S et al (1993) Presence of furin mRNA in cultured bovine endothelial cells and possible involvement of furin in the processing of the endothelin precursor. J Cardiovasc Pharmacol 22(Suppl 8):S7–S10
23. Takahashi M et al (1993) Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem 268(28):21394–21398
24. Xu D et al (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78(3):473–485
25. Sakurai T et al (1991) cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 175(1):44–47
26. Ehrenreich H et al (1990) Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172(6):1741–1748
27. Yu JC, Davenport AP (1995) Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol 114(2):551–557
28. Emori T et al (1991) Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 18(2):165–170
29. Jougasaki M et al (2002) Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. Peptides 23(8):1441–1447
30. Love MP et al (1996) Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 94(9):2131–2137
31. Masaki T et al (1991) Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 84(4):1457–1468
32. Motte S, McEntee K, Naeije R (2006) Endothelin receptor antagonists. Pharmacol Ther 110(3):386–414
33. Boulanger C, Luscher TF (1990) Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85(2):587–590
34. Prins BA et al (1994) Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 269(16):11938–11944
35. Wagner OF et al (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267(23):16066–16068
36. Dupuis J, Goresky CA, Fournier A (1996) Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81(4):1510–1515
37. Thorin E, Clozel M (2010) The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol 60:1–26
38. Vignon-Zellweger N et al (2012) Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci 91(13–14):490–500
39. Clerk A et al (2002) Up-regulation of c-jun mRNA in cardiac myocytes requires the extracellular signal-regulated kinase cascade, but c-Jun N-terminal kinases are required for efficient up-regulation of c-Jun protein. Biochem J 368(Pt 1):101–110
40. MacNulty EE, Plevin R, Wakelam MJ (1990) Stimulation of the hydrolysis of phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine by endothelin, a complete mitogen for Rat-1 fibroblasts. Biochem J 272(3):761–766
41. Anggrahini DW et al (2009) Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc Res 82(1):143–151
42. Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14(6 Pt 2):83S–89S
43. MacCarthy PA et al (2000) Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 101(2):142–147
44. Marshall AK et al (2010) ERK1/2 signaling dominates over RhoA signaling in regulating early changes in RNA expression induced by endothelin-1 in neonatal rat cardiomyocytes. PLoS ONE 5(4):e10027
45. Shimojo N et al (2007) Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 293(1):H474–H481
46. Shimojo N et al (2006) Eicosapentaenoic acid prevents endothelin-1-induced cardiomyocyte hypertrophy in vitro through the suppression of TGF-beta 1 and phosphorylated JNK. Am J Physiol Heart Circ Physiol 291(2):H835–H845
47. Speed JS, Pollock DM (2013) Endothelin, kidney disease, and hypertension. Hypertension 61(6):1142–1145
48. Arai H et al (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348(6303):730–732
49. Sakurai T et al (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348(6303):732–735
50. Sakurai T, Yanagisawa M, Masaki T (1992) Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13(3):103–108
51. Hynynen MM, Khalil RA (2006) The vascular endothelin system in hypertension–recent patents and discoveries. Recent Pat Cardiovasc Drug Discov 1(1):95–108
52. Bourne HR (1997) How receptors talk to trimeric G proteins. Curr Opin Cell Biol 9(2):134–142
53. LaDouceur DM et al (1993) ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem Biophys Res Commun 196(1):209–215
54. MacLean MR, McCulloch KM, Baird M (1994) Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 23(5):838–845
55. Simonson MS, Dunn MJ (1990) Cellular signaling by peptides of the endothelin gene family. FASEB J 4(12):2989–3000
56. Sumner MJ et al (1992) Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 107(3):858–860
57. Hosoda K et al (1991) Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 287(1–2):23–26
58. Davenport AP et al (1993) Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 22(Suppl 8):S22–S25
59. Ogawa Y et al (1991) Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 178(1):248–255
60. Goldie RG et al (1996) The distribution and density of receptor subtypes for endothelin-1 in peripheral lung of the rat, guinea-pig and pig. Br J Pharmacol 117(4):729–735
61. Davie N et al (2002) ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165(3):398–405
62. Mazzuca MQ, Khalil RA (2012) Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 84(2):147–162
63. Liu S et al (2003) Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. J Biol Chem 278(50):49929–49935
64. Alonso D, Radomski MW (2003) The nitric oxide-endothelin-1 connection. Heart Fail Rev 8(1):107–115
65. Sato K et al (1995) Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269(5 Pt 1):L668–L672
66. Muramatsu M et al (1999) Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. Am J Physiol 276(2 Pt 1):L358–L364
67. Clozel M et al (1992) The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186(2):867–873
68. de Nucci G et al (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85(24):9797–9800
69. Haynes WG, Webb DJ (1993) Endothelium-dependent modulation of responses to endothelin-I in human veins. Clin Sci (Lond) 84(4):427–433
70. Verhaar MC et al (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97(8):752–756
71. Pernow J, Modin A (1993) Endothelial regulation of coronary vascular tone in vitro: contribution of endothelin receptor subtypes and nitric oxide. Eur J Pharmacol 243(3):281–286
72. Sauvageau S et al (2006) Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231(6):840–846
73. Sauvageau S et al (2007) Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res 44(5):375–381
74. Dupuis J et al (2000) Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 13(3):135–140
75. Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731–759
76. Sen U et al (2009) Fibrinogen-induced endothelin-1 production from endothelial cells. Am J Physiol Cell Physiol 296(4):C840–C847
77. Evans NJ, Walker JW (2008) Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J 95(1):483–492
78. 2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol 86(8):526–535
79. Pietra GG et al (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43(12 Suppl):25S–32S
80. Stewart DJ et al (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114(6):464–469
81. Takahashi H et al (2001) Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 18(1):5–14
82. Rubin LJ (2012) Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci 91(13–14):517–521
83. Giaid A (1998) Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114(3 Suppl):208S–212S
84. Eddahibi S et al (1995) Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 268(2 Pt 2):H828–H835
85. Chen SJ et al (1997) The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 29(6):713–725
86. Nagendran J et al (2013) Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res 112(2):347–354
87. Chin KM, Kim NH, Rubin LJ (2005) The right ventricle in pulmonary hypertension. Coron Artery Dis 16(1):13–18
88. Farb A, Burke AP, Virmani R (1992) Anatomy and pathology of the right ventricle (including acquired tricuspid and pulmonic valve disease). Cardiol Clin 10(1):1–21
89. Channick R et al (2001) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 20(2):262–263
90. Rubin LJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903
91. Galie N et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493–2537
92. Calabro P et al (2012) Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. Intern Emerg Med 7(5):425–430
93. Cattano D, Doursout MF (2012) Pulmonary hypertension: have we learned enough yet? Intern Emerg Med 7(5):395–397
94. Johnson JA, Cavallari LH (2013) Pharmacogenetics and cardiovascular disease–implications for personalized medicine. Pharmacol Rev 65(3):987–1009
95. Maron BJ et al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807–1816
96. Burkett EL, Hershberger RE (2005) Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45(7):969–981
97. Hershberger RE et al (2010) Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet 3(2):155–161
98. Ponicke K et al (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97(8):744–751
99. McMurray JJ et al (1992) Plasma endothelin in chronic heart failure. Circulation 85(4):1374–1379
100. Omland T et al (1994) Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89(4):1573–1579
101. 2+ modulation. Circ Res 78(2):302–311
102. Piuhola J et al (2003) Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension 41(1):93–98
103. Mulder P et al (1997) Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96(6):1976–1982
104. Zhao XS et al (2006) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114(8):830–837
105. Talukder MA et al (2001) Inotropic response of rabbit ventricular myocytes to endothelin-1: difference from isolated papillary muscles. Am J Physiol Heart Circ Physiol 281(2):H596–H605
106. 2+ signaling in intact myocardium. J Pharmacol Sci 100(5):525–537
107. Nishimaru K, Miura Y, Endoh M (2007) Mechanisms of endothelin-1-induced decrease in contractility in adult mouse ventricular myocytes. Br J Pharmacol 152(4):456–463
108. Namekata I et al (2008) Intracellular mechanisms and receptor types for endothelin-1-induced positive and negative inotropy in mouse ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 376(6):385–395
109. Galie N et al (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46(3):529–535
110. Nicaud V et al (1999) Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Temoins sur l’Infarctus du Myocarde (ECTIM) Study. Am J Hypertens 12(3):304–310
111. Tiret L et al (1999) The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 33(5):1169–1174
112. Charron P et al (1999) Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 20(21):1587–1591
113. Colombo MG et al (2006) ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure. A case-control study. Cardiology 105(4):246–252
114. Tanaka C et al (2004) Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene. Hypertens Res 27(5):367–371
115. Treiber FA et al (2003) Endothelin-1 gene Lys198Asn polymorphism and blood pressure reactivity. Hypertension 42(4):494–499
116. Barden AE et al (2001) Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens 19(10):1775–1782
117. Fraccarollo D et al (1997) Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96(11):3963–3973
118. Yamauchi-Kohno R et al (1999) Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 99(16):2171–2176
119. Sutsch G et al (1998) Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98(21):2262–2268
120. Torre-Amione G et al (2001) Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 103(7):973–980
121. Cotter G et al (2001) Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail 3(4):457–461
122. Anand I et al (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431):347–354
123. Kaluski E et al (2008) Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension–a multi-center randomized study. Cardiology 109(4):273–280
124. Torre-Amione G et al (2003) Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42(1):140–147
125. Jiang BH et al (2011) Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J 37(3):578–586
126. Padeletti M et al (2013) Effect of bosentan on pulmonary hypertension secondary to systolic heart failure. Pharmacology 92(5–6):281–285
127. O’Connor CM et al (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41(9):1452–1457
128. Kirshbom PM et al (2008) The endothelin-1 G5665T polymorphism impacts transplant-free survival for single ventricle patients. J Thorac Cardiovasc Surg 136(1):117–122
129. Messerli FH, Williams B, Ritz E (2007) Essential hypertension. Lancet 370(9587):591–603
130. Kumagae S et al (2010) High level of plasma endothelin-1 predicts development of hypertension in normotensive subjects. Am J Hypertens 23(10):1103–1107
131. Ergul S et al (1996) Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28(4):652–655
132. Campia U, Cardillo C, Panza JA (2004) Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation 109(25):3191–3195
133. Hasegawa K et al (1994) Endothelin-1-selective receptor in the arterial intima of patients with hypertension. Hypertension 23(3):288–293
134. Schiffrin EL et al (1996) Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 33(3):235–248
135. Haynes WG et al (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93(10):1860–1870
136. Ohkita M et al (2012) Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci 119(4):302–313
137. Rautureau Y, Schiffrin EL (2012) Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens 21(2):128–136
138. Lariviere R, Day R, Schiffrin EL (1993) Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 21(6 Pt 2):916–920
139. Barton M et al (1998) ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31(1 Pt 2):499–504
140. Li JS, Lariviere R, Schiffrin EL (1994) Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 24(2):183–188
141. Matsumura Y et al (1999) Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 33(2):759–765
142. Amiri F et al (2008) Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens 26(6):1102–1109
143. Amiri F et al (2010) Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. J Hypertens 28(6):1243–1251
144. Ward RH (1983) Genetic and sociocultural components of high blood pressure. Am J Phys Anthropol 62(1):91–105
145. Benjafield AV, Katyk K, Morris BJ (2003) Association of EDNRA, but not WNK4 or FKBP1B, polymorphisms with essential hypertension. Clin Genet 64(5):433–438
146. Krum H et al (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338(12):784–790
147. Nakov R et al (2002) Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 15(7 Pt 1):583–589
148. Black HR et al (2007) Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9(10):760–769
149. Weber MA et al (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374(9699):1423–1431
150. Bakris GL et al (2010) Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56(5):824–830
151. Raina A, Horn ET, Benza RL (2012) The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists. Transplantation 94(9):885–893
152. Dorent R et al (1994) Endothelin levels after orthotopic heart transplantation. Transplant Proc 26(1):250
153. Ferri C et al (2002) Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. Circulation 105(15):1768–1771
154. Cauduro RL et al (2005) Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 19(4):470–474
155. Simonson MS et al (1999) Inhibition of endothelin-converting enzyme attenuates transplant vasculopathy and rejection in rat cardiac allografts. Transplantation 67(12):1542–1547
156. Takeda Y et al (1995) Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 26(6 Pt 1):932–936